NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8(+) T-cell-mediated immunity and protection

Maraskovsky, Eugene, Sjölander, Sigrid, Drane, Debbie P., Schnurr, Max, Le, Thuy T. T., Mateo, Luis, Luft, Thomas, Masterman, Kelly-Anne, Tai, Tsin-Yee, Chen, Qiyuan, Green, Simon, Sjölander, Anders, Pearse, Martin J., Lemonnier, Francois A., Chen, Weisan, Cebon, Jonathan and Suhrbier, Andreas (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8(+) T-cell-mediated immunity and protection. Clinical Cancer Research, 10 8: 2879-2890. doi:10.1158/1078-0432.CCR-03-0245


Author Maraskovsky, Eugene
Sjölander, Sigrid
Drane, Debbie P.
Schnurr, Max
Le, Thuy T. T.
Mateo, Luis
Luft, Thomas
Masterman, Kelly-Anne
Tai, Tsin-Yee
Chen, Qiyuan
Green, Simon
Sjölander, Anders
Pearse, Martin J.
Lemonnier, Francois A.
Chen, Weisan
Cebon, Jonathan
Suhrbier, Andreas
Title NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8(+) T-cell-mediated immunity and protection
Journal name Clinical Cancer Research   Check publisher's open access policy
ISSN 1078-0432
Publication date 2004-04-15
Sub-type Article (original research)
DOI 10.1158/1078-0432.CCR-03-0245
Volume 10
Issue 8
Start page 2879
End page 2890
Total pages 2
Place of publication United States
Publisher American Association for Cancer Research
Language eng
Subject 1112 Oncology and Carcinogenesis
Abstract NY-ESO-1 is a 180 amino-acid human tumor antigen expressed by many different tumor types and belongs to the family of "cancer-testis" antigens. In humans, NY-ESO-1 is one of the most immunogenic tumor antigens and NY-ESO-1 peptides have been shown to induce NY-ESO-1-specific CD8(+) CTLs capable of altering the natural course of NY-ESO-1-expressing tumors in cancer patients. Here we describe the preclinical immunogenicity and efficacy of NY-ESO-1 protein formulated with the ISCOMATRIX adjuvant (NY-ESO-1 vaccine). In vitro, the NY-ESO-1 vaccine was readily taken up by human monocyte-derived dendritic cells, and on maturation, these human monocyte-derived dendritic cells efficiently cross-presented HLA-A2-restricted epitopes to NY-ESO-1-specific CD8(+) T cells. In addition, epitopes of NY-ESO-1 protein were also presented on MHC class II molecules to NY-ESO-1-specific CD4(+) T cells. The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-gamma and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8(+) CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2(+) NY-ESO-1(+) tumor cells. Finally, C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1. These data illustrate that the NY-ESO-1 vaccine represents a potent therapeutic anticancer vaccine.
Keyword Cell Line, Tumor
Disease Progression
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Epitopes/chemistry
Escherichia coli/metabolism
HLA-A2 Antigen/chemistry
Immunity, Cellular
Immunoglobulin G/chemistry
Immunohistochemistry
Melanoma, Experimental
Membrane Proteins/chemistry*
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 58 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 61 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 31 Mar 2010, 09:43:22 EST by Therese Egan on behalf of Faculty Of Health Sciences